A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Study Locations
-
-
-
Buenos Aires, Argentina, C1199ABB
- Recruiting
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentina, C1426ANZ
- Recruiting
- Instituto Alexander Fleming
-
Buenos Aires, Argentina, C1118
- Recruiting
- Hospital Aleman
-
Córdoba, Argentina, X5016KEH
- Recruiting
- Hospital Privado Centro Medico de Cordoba
-
Pilar, Argentina, 1629
- Recruiting
- Hospital Universitario Austral
-
-
-
-
-
Bedford Park, Australia, 5042
- Recruiting
- Flinders Medical Centre
-
Birtinya, Australia, 4575
- Recruiting
- Sunshine Coast University Hospital
-
Concord, Australia, 2139
- Recruiting
- Concord Repatriation General Hospital
-
Fitzroy, Australia, 3065
- Recruiting
- St Vincents Hospital Melbourne
-
Wollongong, Australia, 2500
- Recruiting
- Wollongong Hospital
-
-
-
-
-
Argenteuil, France, 95107
- Recruiting
- Centre Hospitalier Victor Dupouy
-
Bayonne, France, 64100
- Recruiting
- Centre Hospitalier de la Cote Basque
-
La Tronche, France, 38700
- Recruiting
- CHU de Grenoble
-
Le Mans, France, 72100
- Recruiting
- Centre de Cancerologie de la Sarthe
-
Nantes, France, 44000
- Recruiting
- CHU Nantes - Hotel Dieu
-
Quimper, France, 29000
- Recruiting
- Centre Hospitalier de Quimper Cornouaille
-
-
-
-
-
Alexandroupoli, Greece, 681 00
- Recruiting
- Uni General Hospital of Alexandroupolis
-
Athens, Greece, 11528
- Recruiting
- Alexandra General Hospital of Athens
-
Athens, Greece, 115 25
- Recruiting
- 251 Air Force General Hospital
-
Piraeus, Greece, 18537
- Recruiting
- Metaxa Cancer Center Hospital Of Piraeus
-
Rio, Greece, 265 04
- Recruiting
- General University Hospital of Patras
-
Thessaloniki, Greece, 54642
- Recruiting
- Hippokration Hospital
-
Thessaloniki, Greece, 546 39
- Recruiting
- Theageneio Cancer Hospital
-
-
-
-
-
Budapest, Hungary, 1088
- Recruiting
- Semmelweis Egyetem
-
Budapest, Hungary, 1097
- Recruiting
- Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
-
Budapest, Hungary, 1122
- Recruiting
- Orszagos Onkologiai Intezet
-
Pécs, Hungary, 7624
- Recruiting
- Pecsi Tudomanyegyetem Klinikai Kozpont
-
Szeged, Hungary, 6725
- Recruiting
- Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar
-
-
-
-
-
Ampang, Malaysia, 68000
- Recruiting
- Hospital Ampang
-
George Town, Malaysia, 10450
- Recruiting
- Hospital Pulau Pinang
-
Johor Bharu, Malaysia, 80100
- Recruiting
- Hospital Sultanah Aminah
-
Kota Kinabalu, Malaysia, 88586
- Recruiting
- Hospital Queen Elizabeth
-
Kuching, Malaysia, 93586
- Recruiting
- Sarawak General Hospital
-
-
-
-
-
Braga, Portugal, 4710 243
- Recruiting
- Uls Braga - Hosp. Braga
-
Lisbon, Portugal, 1099 023
- Recruiting
- Ipo Lisboa
-
Lisbon, Portugal, 1998 018
- Recruiting
- Hosp. Cuf Descobertas
-
Porto, Portugal, 4200 319
- Recruiting
- Uls Sao Joao - Hosp. Sao Joao
-
Porto, Portugal, 4050 342
- Recruiting
- Uls Santo Antonio - Hosp. Santo Antonio
-
Vila Nova de Gaia, Portugal, 4434 502
- Recruiting
- Uls Gaia Espinho
-
-
-
-
-
Barcelona, Spain, 08041
- Recruiting
- Hosp. de La Santa Creu I Sant Pau
-
León, Spain, 24071
- Recruiting
- Hosp. de Leon
-
Madrid, Spain, 28046
- Recruiting
- Hosp. Univ. La Paz
-
Madrid, Spain, 28055
- Recruiting
- Hosp. Blua Sanitas Valdebebas
-
Málaga, Spain, 29010
- Recruiting
- Hosp Regional Univ de Malaga
-
Pamplona, Spain, 31008
- Recruiting
- Hosp. de Navarra
-
Valencia, Spain, 46017
- Recruiting
- Hosp. Univ. Dr. Peset
-
-
-
-
-
Falun, Sweden, 791 82
- Recruiting
- Falu Lasarett Medicinkliniken Falun
-
Gothenburg, Sweden, 413 45
- Recruiting
- Sahlgrenska Universitetssjukhuset
-
Lund, Sweden, 221 85
- Recruiting
- Skanes universitetssjukhus
-
Stockholm, Sweden, 141 86
- Recruiting
- Karolinska University Hospital Huddinge
-
Uppsala, Sweden, 752 37
- Recruiting
- Akademiska Sjukhuset
-
-
-
-
Arizona
-
Goodyear, Arizona, United States, 85338
- Recruiting
- City of Hope Phoenix
-
-
California
-
Beverly Hills, California, United States, 90211
- Recruiting
- Beverly Hills Cancer Center (BHCC)
-
Irvine, California, United States, 92618
- Recruiting
- City of Hope Orange County Lennar Foundation Cancer Center
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Colorado Blood Cancer Institute
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Recruiting
- Washington University School Of Medicine
-
-
Ohio
-
Columbus, Ohio, United States, 43214
- Recruiting
- Ohio Health Research Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Institute
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- University of Utah Huntsman Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
- Received at least 1 prior lines of antimyeloma therapy
- Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
- Have clinical laboratory values meeting the criteria specified in the protocol
Exclusion criteria:
- Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
- Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
- Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
- Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A: Tocilizumab + Ramantamig
Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier). |
Ramantamig will be administered as subcutaneous (SC) injection.
Other Names:
Tocilizumab will be administered as intravenous (IV) injection. |
|
Placebo Comparator: Arm B: Placebo + Ramantamig
Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier). |
Ramantamig will be administered as subcutaneous (SC) injection.
Other Names:
Placebo (saline) will be administered as IV injection. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
Time Frame: By the end of Day 28 from first ramantamig dose
|
Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported. |
By the end of Day 28 from first ramantamig dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
Time Frame: By the end of Day 28 from first ramantamig dose
|
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the end of day 28 from first ramantamig dose, respectively, will be reported. |
By the end of Day 28 from first ramantamig dose
|
|
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
Time Frame: Up to 38 months
|
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 during ramantamig treatment will be reported. |
Up to 38 months
|
|
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
Time Frame: Up to 38 months
|
Percentage of participants with re-occurrence of CRS with ASTCT Grade >=2 after the initial occurrence of treatment-emergent Grade >=2 CRS event will be reported. |
Up to 38 months
|
|
Percentage of Participants with Re-occurrence of CRS for All Grades
Time Frame: Up to 38 months
|
Percentage of participants with re-occurrence of CRS for all Grades will be reported. |
Up to 38 months
|
|
Overall Response
Time Frame: Up to 38 months
|
Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria. |
Up to 38 months
|
|
Complete Response (CR) or Better
Time Frame: Up to 38 months
|
CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria. |
Up to 38 months
|
|
Very Good Partial Response (VGPR) or Better
Time Frame: Up to Month 38
|
VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria. |
Up to Month 38
|
|
Duration of Response (DoR)
Time Frame: Up to 38 months
|
DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first. |
Up to 38 months
|
|
Time to Response (TTR)
Time Frame: Up to 38 months
|
TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response. |
Up to 38 months
|
|
Progression-Free Survival (PFS)
Time Frame: Up to Month 38
|
PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria. |
Up to Month 38
|
|
Time to Subsequent Antimyeloma Therapy
Time Frame: Up to Month 38
|
Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event. |
Up to Month 38
|
|
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
Time Frame: Up to 38 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event. |
Up to 38 months
|
|
Percentage of Participants with Abnormalities in Laboratory Parameters
Time Frame: Up to 38 months
|
Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported. |
Up to 38 months
|
|
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
Time Frame: Up to 38 Months
|
Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported. |
Up to 38 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Hemic and Lymphatic Diseases
- Multiple Myeloma
- tocilizumab
Other Study ID Numbers
Other Study ID Numbers
- 79635322MMY2002
- 2025-524793-42 (EudraCT Number)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.